Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry

Journal of Clinical Oncology

Volumn 26, Issue 13, 2008, Pages 2155-2161

  Hillner, Bruce E ^a   Siegel, Barry A ^a   Liu, Dawei ^a   Shields, Anthony F ^a   Gareen, Ilana F ^a   Hanna, Lucy ^a   Stine, Sharon Hartson ^a   Coleman, R Edward ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFIDENCE INTERVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RISK ASSESSMENT; TUMOR BIOPSY; BIOPSY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GOVERNMENT; MEDICARE; MIDDLE AGED; MULTICENTER STUDY; PALLIATIVE THERAPY; PATIENT CARE PLANNING; PATIENT SELECTION; PROSPECTIVE STUDY; RADIOGRAPHY; REGISTER; RISK; SCINTISCANNING; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; BIOPSY; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); FEMALE; HUMANS; MALE; MEDICARE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; ODDS RATIO; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; PATIENT CARE PLANNING; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGISTRIES; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 43749121858     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.5631     Document Type: Article

References (30)

1. McClellan MB, Tunis SR: Medicare Coverage of ICDs. N Engl J Med 352:222-224, 2005
2. Tunis SR, Carino TV, Williams RD II, et al: Federal initiatives to support rapid learning about new technologies. Health Aff (Millwood) 26:w140-w149, 2007
3. Tunis SR, Kang JL: Perspective: Improvements in Medicare coverage of new technology. Health Aff (Millwood) 20:83-85, 2001
4. Tunis SR, Pearson SD: Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood) 25:1218-1230, 2006
5. Centers for Medicare & Medicaid Service: Pub 100-03 Medicare National Coverage Determinations, Transmittal 31. http://www.cms.hhs.gov/transmittals/ downloads/R31NCD.pdf
6. Centers for Medicare & Medicaid Service: National coverage determinations with data collection as a condition for coverage: Coverage with evidence development. http://www.cms.hhs.gov/transmittals/downloads/R956CP.pdf
7. Kelloff GJ, Hoffman JM, Johnson B, et al: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-2808, 2005
8. von Schulthess GK, Steinert HC, Hany TF: Integrated PET/CT: Current applications and future directions. Radiology 238:405-422, 2006
9. Centers for Medicare & Medicaid Services: Decision memo for positron emission tomography (FDG) for brain, cervical, ovarian, pancreatic, small cell lung, and testicular cancers. http://www.cms.hhs.gov/transmittals/downloads/ R514CP.pdf
10. Hillner BE, Siegel BA, Liu D, et al: The National Oncologic PET Registry (NOPR): Design and analysis plan. J Nucl Med 48:1901-1908, 2007
11. Lindsay MJ, Siegel BA, Tunis SR, et al: The National Oncologic PET Registry: Expanded Medicare coverage for PET under coverage with evidence development. AJR Am J Roentgenol 188:1109-1113, 2007
12. Gambhir SS, Czernin J, Schwimmer J, et al: A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S, 2001
13. Tucker R, Coel M, Ko J, et al: Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: First year's experience in a clinical center. J Clin Oncol 19:2504-2508, 2001
14. Gopalan D, Griffiths D, Townsend C, et al: Fluorodeoxyglucose positron emission tomography in clinical oncology: The referrer's perspective. Nucl Med Commun 23:1041-1046, 2002
15. Hillner BE, Tunuguntla R, Fratkin M: Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 22:4147-4156, 2004
16. Herder G, Van Tinteren H, Comans E, et al: Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer. Thorax 58:47-51, 2003
17. Kalff V, Hicks RJ, MacManus MP, et al: Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study. J Clin Oncol 19:111-118, 2001
18. Kalff V, Hicks RJ, Ware RE, et al: The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: A prospective study. J Nucl Med 43:492-499, 2002
19. Schöder H, Herrmann K, Gonen M, et al: 2-[18F]Fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11:4761-4769, 2005
20. Simcock B, Neesham D, Quinn M, et al: The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 103:271-276, 2006
21. Heinrich S, Goerres GW, Schafer M, et al: Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242:235-243, 2005
22. Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA 290:1624-1632, 2003
23. Wittenberg J, Fineberg HV: Evaluating efficacy. AJR Am J Roentgenol 134:1277-1279, 1980
24. Wittenberg J, Fineberg HV, Ferrucci JT Jr, et al: Clinical efficacy of computed body tomography, II. AJR Am J Roentgenol 134:1111-1120, 1980
25. Wittenberg J, Fineberg HV, Black EB, et al: Clinical efficacy of computed body tomography. AJR Am J Roentgenol 131:5-14, 1978
26. Mallett S, Deeks JJ, Halligan S, et al: Systematic reviews of diagnostic tests in cancer: Review of methods and reporting. BMJ 333:413, 2006
27. Lauer MS, Murthy SC, Blackstone EH, et al: [18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: Impact of verification bias. Arch Intern Med 167:161-165, 2007
28. Herder GJM, Kramer H, Hoekstra OS, et al: Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: A Dutch Cooperative randomized study. J Clin Oncol 24:1800-1806, 2006
29. Veit-Haibach P, Kuehle CA, Beyer T, et al: Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 296:2590-2600, 2006
30. Iglehart JK: The new era of medical imaging: Progress and pitfalls. N Engl J Med 354:2822-2828, 2006